胃肠安丸对IBS-D青壮年患者的临床疗效及对血清TNF-α、IL-6的影响

Clinical Efficacy of Weichang'an Wan in Young and Middle-Aged Patients with IBS-D and Its Effects on Serum TNF-α and IL-6

摘要

目的：探究胃肠安丸对腹泻型肠易激综合征（diarrhea-predominant irritable bowel syndrome，IBS-D）青壮年患者的临床疗效及其对血清白细胞介素-6（interleukin-6，IL-6）、肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）的影响。方法：2024-06—2025-06就诊于邢台市人民医院消化内科门诊IBS-D患者90例，年龄15~44岁，采用随机生成器将其分为观察组和对照组各45例。观察组口服胃肠安丸，对照组口服匹维溴铵，对比两组患者用药前后的临床疗效、IL-6及TNF-α水平的变化，比较两组IBS患者生活质量评分（irritable bowel syndrome quality of life，IBS-QOL）、IBS病情严重程度评分（irritable bowel syndrome severity scoring system，IBS-SSS）、汉密尔顿焦虑量表（Hamilton anxiety scale，HAMA）及汉密尔顿抑郁量表（Hamilton depression scale，HAMD）评分的变化。结果：观察组总有效率高于对照组（P<0.05），治疗后观察组TNF-α水平低于对照组（P<0.05），IBS-QOL评分高于对照组，HAMA、HAMD评分均低于对照组（P<0.05）。结论：胃肠安丸能有效改善IBS-D青壮年患者的临床症状，改善患者炎症水平，改善情绪，提高生活质量。

Abstract

Objective: To investigate the clinical efficacy of Weichang'an Wan in young adults with diarrhea-predominant irritable bowel syndrome (IBS-D) and its effects on serum IL-6 and TNF-α levels. Methods: Ninety patients aged 15~44 years who met the IBS-D diagnostic criteria were selected and randomly divided into an observation group(45 cases) and a control group(45 cases) using a random generator. The observation group received oral Weichang'an Wan, while the control group received oral pinaverium bromide. Clinical efficacy, serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels before and after treatment were compared between the two groups. Additionally, changes in irritable bowel syndrome quality of life (IBS-QOL), irritable bowel syndrome severity scoring system (IBS-SSS), Hamilton anxiety scale (HAMA), and Hamilton depression scale (HAMD) scores before and after treatment were compared. Results: The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the TNF-α level in the observation group was lower than that in the control group (P<0.05). The IBS-QOL score of the observation group was higher than that of the control group, while the HAMA and HAMD scores were lower than those of the control group (P<0.05). Conclusion: Weichang'an Wan can effectively improve clinical symptoms in young and middle-aged IBS-D patients, reduce inflammation levels, alleviate emotional distress, and enhance quality of life.

关键词

腹泻型肠易激综合征 / 胃肠安丸 / 青壮年 / 情绪障碍 / 炎症 / 生活质量

Key words

diarrhea-predominant irritable bowel syndrome / weichang'an wan / young adults / emotional disorders / inflammation / quality of life

参考文献

[1] 罗梅, 熊理守. 肠易激综合征诊断的研究进展[J]. 国际消化病杂志, 2023, 43(2): 77-80.

[2] 中国中西医结合学会消化系统疾病专业委员会. 肠易激综合征中西医结合诊疗专家共识(2025年)[J]. 中国中西医结合消化杂志, 2025, 33(3): 183-194.

[3] Ami D Sperber, Shrikant I Bangdiwala, Douglas A Drossman, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study[J]. Gastroenterology, 2021, 160(1): 99-114.e3.

[4] 赵尔樱, 周佳玮, 褚海云, 等. 肠易激综合征流行病学与致病因素研究进展[J]. 中国公共卫生, 2021, 37(4): 764-768.

[5] Alexander C Ford, Ami D Sperber, Maura Corsetti, et al. Irritable bowel syndrome[J]. Lancet, 2020, 396(10263): 1675-1688.

[6] Michael Camilleri. Diagnosis and treatment of irritable bowel syndrome: a review[J]. JAMA, 2021, 325(9): 865-877.

[7] 孙秀娟, 李岳来. 胃肠安丸治疗腹泻型肠易激综合征临床观察[J]. 按摩与康复医学, 2015(10): 84-85.

[8] 高广周, 姚红梅, 张晓明, 等. 氟哌噻吨美利曲辛联合胃肠安丸治疗腹泻型肠易激综合征临床效果研究[J]. 河北医科大学学报, 2016, 37(12): 1383—1386, 1390.

[9] 刘静. 胃肠安丸联合活菌制剂治疗腹泻型肠易激综合征临床疗效观察[J]. 湖北中医杂志, 2021, 43(10): 27-29.

[10] 李彦楠, 杨丽旋, 赵钟辉, 等. 《2020年中国肠易激综合征专家共识意见》解读[J]. 中国临床医生杂志, 2021, 49(10): 1151-1155.

[11] 郭慧敏. 胃肠安丸主要药味及其配伍调节胃肠运动的研究[D]. 天津: 天津大学, 2014.

[12] 张朦朦, 费贵军. 肿瘤坏死因子—α在肠易激综合征发病机制中的作用[J]. 胃肠病学, 2018, 23(12): 752-754.

[13] Patrick A Hughes, Andrea M Harrington, Joel Castro, et al. Sensory neuro—immune interactions differ between irritable bowel syndrome subtypes[J]. Gut, 2013, 62(10): 1456-1465.

[14] 杨秋蕊, 姜迪, 孟棵, 等. 基于网络药理学探讨胃肠安丸治疗肠易激综合征的分子机制[J]. 中医杂志, 2021, 62(7): 628-634+644.

[15] 刘修波, 卫红军, 张巍巍, 等. IL—6、IL—23在肠易激综合征患者肠黏膜的表达及意义[J]. 现代生物医学进展, 2011, 11(7): 1250—1252, 1288.